Physician profile
Bryan Leo Lu
NPI 1598510117
$3,920.72
in general payments reported to CMS, 2019-2025
20 companies · $2,789 in 2025
The $2,789 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,132 · 2025: $2,789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,921.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,920.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,085.29 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $490.49 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $432.40 | 2024-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $319.29 | 2025 | Ozempic, Rybelsus |
| Abbvie INC. | $297.28 | 2024-2025 | |
| Kowa Pharmaceuticals America, INC. | $184.67 | 2024-2025 | Zoryve |
| Merck Sharp & Dohme LLC | $152.16 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Pfizer INC. | $148.96 | 2025 | |
| Agios Pharmaceuticals, INC. | $139.59 | 2024 | Pyrukynd |
| Gilead Sciences, INC. | $119.55 | 2025 | Livdelzi |
| Lilly USA, LLC | $118.00 | 2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $77.30 | 2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.13 | 2025 | Xifaxan |
| Esperion Therapeutics, INC. | $68.04 | 2024-2025 | Nexletol |
| Phathom Pharmaceuticals, INC. | $61.92 | 2025 | Voquezna |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $58.45 | 2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $32.42 | 2025 | |
| Lundbeck LLC | $25.35 | 2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.13 | 2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $18.30 | 2025 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Lu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.